Use of Hormone Replacement in Females with Endocrine Disorders

Christin-Maître, Sophie

doi:10.1159/000457125

Cited by 13 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matthews et al [13] from the United Kingdom have described a consensus from the British Society for Paediatric Endocrinology and Diabetes on hormone supplementation for pubertal induction in girls. Christin-Maitre [14] published a review on the use of hormone replacement in females with endocrine disorders. However, the Cincinnati guidelines do not cover pubertal induction in depth while other papers do not deal specifically with TS.…”

Section: Introductionmentioning

confidence: 99%

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

et al. 2019

View full text Add to dashboard Cite

Background: Most girls with Turner syndrome (TS) require pubertal induction with estrogen, followed by long term replacement. However, no adequately powered prospective studies comparing transdermal with oral 17β-estradiol administration exist. This reflects the difficulty of securing funding to study a rare condition with relatively low morbidity/mortality when competing against conditions such as cancer and vascular disease. Protocol Consensus: The TS Working Group of the European Society for Paediatric Endocrinology (ESPE) has agreed to both a 3-year oral and a 3-year transdermal regimen for pubertal induction. Prerequisites include suitable 17β-estradiol tablets and matrix patches to allow the delivery of incremental doses based on body weight. Study Proposal: An international prospective cohort study with single centre analysis is proposed in which clinicians and families are invited to choose either of the agreed regimens, usually starting at 11 years. We hypothesise that pubertal induction with transdermal estradiol will result in better outcomes for some key parameters. The primary outcome measure chosen is height gain during the induction period. Analysis: Assessment of the demographics and drop-out rates of patients choosing either oral or transdermal preparations; and appropriate analysis of outcomes including pubertal height gain, final height, liver enzyme and lipid profile, adherence/acceptability, cardiovascular health, including systolic and diastolic blood pressure and aortic root diameter and bone health. Conclusion: The proposed model of prospective data collection according to internationally agreed protocols aims to break the current impasse in obtaining evidence-based management for TS and could be applied to other rare paediatric endocrine conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…OTCT is a promising approach for addressing this diverse set of side effects, given the ability of transplanted ovarian tissue to produce the full panel of ovarian hormones at physiologic levels and intervals, thereby restoring the reciprocity of the hypothalamus–pituitary–ovary (HPO) axis. In comparison, hormone replacement therapy (HRT), the only clinically approved treatment for POI, delivers only estradiol (and progesterone when indicated) [ 4 , 5 ]. This course of treatment does not recapitulate the daily pulsatility and monthly cyclicity characteristics of ovarian hormone production.…”

Section: Introductionmentioning

confidence: 99%

Effect of Donor Age on Endocrine Function of and Immune Response to Ovarian Grafts

Wall,

Garcia de Mattos Barbosa,

Hanby

et al. 2024

IJMS

View full text Add to dashboard Cite

Premature loss of ovarian function (POI) is associated with numerous negative side effects, including vasomotor symptoms, sleep and mood disturbances, disrupted urinary function, and increased risks for osteoporosis and heart disease. Hormone replacement therapy (HRT), the standard of care for POI, delivers only a subset of ovarian hormones and fails to mimic the monthly cyclicity and daily pulsatility characteristic of healthy ovarian tissue in reproductive-aged individuals whose ovarian tissue contains thousands of ovarian follicles. Ovarian tissue allografts have the potential to serve as an alternative, cell-based HRT, capable of producing the full panel of ovarian hormones at physiologically relevant doses and intervals. However, the risks associated with systemic immune suppression (IS) required to prevent allograft rejection outweigh the potential benefits of comprehensive and dynamic hormone therapy. This work investigates whether the age of ovarian tissue donor animals affects the function of, and immune response to, subcutaneous ovarian grafts. We performed syngeneic and semi-allogeneic ovarian transplants using tissue from mice aged 6–8 (D7) or 20–22 (D21) days and evaluated ovarian endocrine function and immune response in a mouse model of POI. Our results revealed that tissue derived from D7 donors, containing an ample and homogeneous primordial follicle reserve, was more effective in fully restoring hypothalamic–pituitary–ovarian feedback. In contrast, tissue derived from D21 donors elicited anti-donor antibodies with higher avidity compared to tissue from younger donors, suggesting that greater immunogenicity may be a trade-off of using mature donors. This work contributes to our understanding of the criteria donor tissue must meet to effectively function as a cell-based HRT and explores the importance of donor age as a factor in ovarian allograft rejection.

show abstract

“…HRT delivers constant doses of estrogen and progesterone, reconstituting ovarian function only partially (7), and precluding ovarianbody homeostasis. Furthermore, the long-term safety and efficacy of HRT to induce puberty has yet to be established (8).…”

Section: Introductionmentioning

confidence: 99%

Human Ovarian Follicles Xenografted in Immunoisolating Capsules Survive Long Term Implantation in Mice

et al. 2022

View full text Add to dashboard Cite

Female pediatric cancer survivors often develop Premature Ovarian Insufficiency (POI) owing to gonadotoxic effects of anticancer treatments. Here we investigate the use of a cell-based therapy consisting of human ovarian cortex encapsulated in a poly-ethylene glycol (PEG)-based hydrogel that replicates the physiological cyclic and pulsatile hormonal patterns of healthy reproductive-aged women. Human ovarian tissue from four donors was analyzed for follicle density, with averages ranging between 360 and 4414 follicles/mm3. Follicles in the encapsulated and implanted cryopreserved human ovarian tissues survived up to three months, with average follicle densities ranging between 2 and 89 follicles/mm3 at retrieval. We conclude that encapsulation of human ovarian cortex in PEG-based hydrogels did not decrease follicle survival after implantation in mice and was similar to non-encapsulated grafts. Furthermore, this approach offers the means to replace the endocrine function of the ovary tissue in patients with POI.

show abstract

Use of Hormone Replacement in Females with Endocrine Disorders

Cited by 13 publications

References 51 publications

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

Effect of Donor Age on Endocrine Function of and Immune Response to Ovarian Grafts

Human Ovarian Follicles Xenografted in Immunoisolating Capsules Survive Long Term Implantation in Mice

Contact Info

Product

Resources

About